CN105025907B - 动物双歧杆菌动物亚种菌株 - Google Patents
动物双歧杆菌动物亚种菌株 Download PDFInfo
- Publication number
- CN105025907B CN105025907B CN201380065461.0A CN201380065461A CN105025907B CN 105025907 B CN105025907 B CN 105025907B CN 201380065461 A CN201380065461 A CN 201380065461A CN 105025907 B CN105025907 B CN 105025907B
- Authority
- CN
- China
- Prior art keywords
- bacterial strain
- composition
- purposes
- cncm
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 14
- 230000001580 bacterial effect Effects 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 210000000105 enteric nervous system Anatomy 0.000 claims abstract description 22
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 36
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 36
- 241000894006 Bacteria Species 0.000 claims description 30
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 29
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 11
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 9
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 208000010643 digestive system disease Diseases 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 210000000936 intestine Anatomy 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 230000000116 mitigating effect Effects 0.000 claims description 5
- 206010022678 Intestinal infections Diseases 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 230000005176 gastrointestinal motility Effects 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 235000021001 fermented dairy product Nutrition 0.000 claims description 3
- 208000027819 intestinal motility disease Diseases 0.000 claims description 3
- 230000008855 peristalsis Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 235000020167 acidified milk Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 102100021851 Calbindin Human genes 0.000 description 2
- -1 D- galactolipin Chemical compound 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 2
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 2
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000004179 neuropil Anatomy 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 1
- 241000949031 Citrobacter rodentium Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种新的动物双歧杆菌动物亚种菌株，其尤其能够改善肠神经系统的功能，以及包括所述新的菌株的组合物。
Description
技术领域
本发明涉及一种新的动物双歧杆菌动物亚种(Bifidobacterium animalisssp.animalis)菌株。此菌株尤其能够通过增加肠神经系统(ENS)的血管活性肠肽(VIP)水平来改善肠神经系统的功能，以例如促进肠道运动性或屏障完整性的功能。因此，此菌株可用于预防和/或减轻胃肠不适或胃肠疾病。
背景技术
肠神经系统(ENS)是整合的神经系统，其沿肠道形成2个主要的具有功能特异性作用的神经丛(Furness,J.Auton.Nerv.Syst.,81(1-3):87-96,2000)。位于纵肌和环状肌之间的肠肌丛包含主要参与控制胃肠(GI)运动性的神经元。位于环状肌和粘膜之间的黏膜下神经丛包含主要参与控制肠上皮屏障(IEB)功能的神经元。肠神经元通过释放作用于肠神经元支配的靶细胞的神经介质来控制GI功能。
对于消化系统，神经介质VIP诱导平滑肌松弛(低级食管括约肌、胃和胆囊)、刺激水分泌至胰液和胆汁中，并使得抑制胃酸分泌和自肠腔中的吸收。其在肠道中的作用是极大地刺激了水和电解质的分泌，以及扩张肠平滑肌、扩张周边血管、刺激胰碳酸氢盐的分泌并抑制由胃泌素刺激的胃酸分泌。这些影响共同作用以增强运动性。因此，增加VIP有益地改善了胃肠道肌肉的松弛。
肠上皮屏障由极化的特异化细胞的连续单层构成，特异化细胞通过控制屏障渗透性以及上皮细胞极性的紧密的连接相关蛋白如紧密连接蛋白-1(ZO-1)而聚在一起。体外和体内的研究表明，益生菌可以通过调节ZO-1来影响上皮抵抗力并降低渗透性(Eun等人,APMIS,119(1):49-56,2011；Miyauchi等人,J.Dairy Sci.,92(6):2400-8,2009)。由ENS合成的神经介质也参与了肠道渗透性调节(等人,Am.J.Physiol.Gastrointest.Liver Physiol.,275:G95-103,1998；Hayden等人,Am.J.Physiol.Regul.Integr.Comp.Physiol.,278:R1589-94,2000；Neunlist等人,Am.J.Physiol.Gastrointest.Liver Physiol.,285(5):G1028-36,2003)。例如，在由新生儿母体分离所诱导的结肠中的增强的乙酰胆碱的神经元合成导致了大鼠中上皮细胞旁渗透性的增加(Gareau等人,Am.J.Physiol.Gastrointest.Liver Physiol.,293:G198-203,2007)。相比之下，由粘膜下神经元所释放的血管活性肠肽(VIP)通过调节紧密连接蛋白ZO-1在肠上皮细胞中的表达增加了IEB的抵抗力(Neunlist等人,J.Intern.Med.,263(6):577-83,2008)进一步增强VIP在调节屏障功能中的作用的最近研究表明VIP增加了在小鼠的由鼠类柠檬酸杆菌(Citrobacter rodentium)诱导的结肠炎中的屏障抵抗力(Conlin等人,Am.J.Physiol.Gastrointest.Liver Physiol.,297(4):G735-50,2009)。
数项研究测量了一些益生菌对ENS神经介质(包括VIP)的作用。Kamm等人(Neurogastrointest.Motil.,16:53-60,2004)公开了布拉氏酵母菌(Saccharomycesboulardii)对减少钙结合蛋白-28k(CALB)的作用，而对猪空肠的其它神经元标记物(ChAT、VIP、SP、NF-160等)没有作用。Metugriachuk等人(Rejuvenation Res.,9:342-345,2006)公开了在年老的Wistar大鼠的小肠和大肠的运动性上的共生制备显著地增加了小肠和结肠的肌电活性，并导致VIP的mRNA表达增加，但对VIP浓度没有显著的作用。
已知细菌菌株可提供与健康相关的益处。这样的菌株通常被称为益生菌，并用于食品。需要新的可以引入到食品中且具有改良的与健康相关的益处和/或其它益处如感官性质和/或可加工性的菌株。
在国际申请WO 2011/148219中，发现包括乳酸菌的组合物在ENS中增加了VIP水平，从而提高了ENS功能。这些乳酸菌尤其是植物乳杆菌(Lactobacillus plantarum)CNCMI-4318、短双歧杆菌(Bifidobacterium breve)CNCM I-2219、动物双歧杆菌乳酸菌亚种(Bifidobacterium animalis ssp.lactis)CNCM I-2494和短双歧杆菌(Bifidobacteriumbreve)CNCM I-4321。
发明内容
在本文中，本发明人鉴定了一种新的细菌菌株，特别地，其尤其可以调节肠神经系统以促进肠道运动性和屏障完整性功能，并且特别地，其所增加的VIP水平多于WO 2011/148219中所公开的菌株。此菌株被归类为动物双歧杆菌动物亚种菌株，并根据布达佩斯条约在2012年3月6日保藏于作为国际保藏机构的CNCM(Collection Nationale de Culturesde Microorganismes，法国国家微生物保藏中心)，编号I-4602。
因此，本发明涉及动物双歧杆菌动物亚种CNCM I-4602菌株。
此菌株的特征如下：
-菌落形态(固体MRS+半胱氨酸，于37℃72h，厌氧条件)：小的、圆形的且白的、规则的且半透明的菌落；
-微观形态(液体MRS+半胱氨酸，于37℃16h，厌氧条件)：厚的、大的、两极的、葫芦形杆菌；
-下列底物的发酵(API 50CH条上，API MRS培养基中，于37℃48h)：L-阿拉伯糖、D-木糖、D-半乳糖、D-葡萄糖、D-麦芽糖、D-蜜二糖、D-蔗糖和D-棉子糖；
-生化鉴定(API 20A条上，API 20A培养基中于36℃24h)：无芽孢，革兰氏染色阳性，棒状，在存在D-葡萄糖、D-蔗糖、D-麦芽糖、水杨苷、D-木糖、L-阿拉伯糖和D-棉子糖、明胶和七叶苷水解作用的情况下酸化；
-所检测到的酶活性(API ZYM条上，于37℃4h)：酯酶(C4)、亮氨酸芳基酰胺酶、胱氨酸芳基酰胺酶、α-半乳糖苷酶、β-半乳糖苷酶和α-葡糖苷酶。
本发明还包括衍生自本发明的菌株的仍对VIP有活性的突变菌株或遗传转化菌株。这些突变体或遗传转化菌株可以是其中一种或多种亲本菌株的内源基因被突变的菌株，例如以修改其一些代谢性质(例如其发酵糖类的能力、其对酸度的抗性、其运送至胃肠道的生存力、其后酸化或其代谢物生产)。它们还可以是用一个或多个目标基因遗传转化亲本菌株所获得的菌株，例如以赋予所述菌株另外的生理特征，或以使其表达希望通过所述菌株施用的具有治疗或疫苗兴趣的蛋白。
本发明的菌株以及如上所定义的突变体可用作益生菌。其可用于预防和/或减轻胃肠不适或胃肠疾病。菌株增加了受试者中肠神经系统的血管活性肠肽(VIP)水平。其可以在施用后抑制食品和/或受试者中的病原体的生长。其可以例如通过增加肠上皮细胞的跨上皮电阻(TEER)来提供改善的肠道屏障性质。其可以借由发酵和/或消化提供目标短链脂肪酸的生产，例如增加的产量或改善的脂肪酸组成。其可以借由发酵和/或消化提供降低的气体产生。其可以对胃应激具有感兴趣的抵抗力。其可以例如为新生哺乳动物尤其是新生人类提供良好的胃肠运动行性质。其可以促进肠神经系统和肠道功能以及胃肠运动性的成熟，从而尤其是降低胃肠转运时间、增加胃肠肌肉收缩力、改善胃肠蠕动、预防延迟的胃排空、增加胃肠系统的协调收缩、降低胎粪排泄时间、降低出生后胃肠运动开始的时间并允许在新生哺乳动物例如新生人类出生后的早期肠道喂养。此菌株可以例如在存在维生素K的情况下在发酵乳制品中呈现出良好的生长和/或存活。
本发明还涉及包含一种或多种其它的(益生的或非益生的)细菌菌株的组合物，例如一种或多种选自乳杆菌(Lactobacillus)、乳球菌(Lactococcus)、链球菌(Streptococcus)和双歧杆菌(Bifidobacteria)属的细菌菌株。特别地，这类其它菌株可包括一种或多种嗜热链球菌(Streptococcus thermophilus)的菌株和/或一种或多种保加利亚乳杆菌(Lactobacillus bulgaricus)的菌株。
根据本发明的这一组合物可有利地包括选自短双歧杆菌CNCM I-4321、短双歧杆菌CNCM I-2219、动物双歧杆菌乳酸菌亚种CNCM I-2494、植物乳杆菌CNCM I-4318、两歧双歧杆菌CNCM I-4319和鼠李糖乳杆菌CNCM I-4316中的至少一种细菌菌株。两歧双歧杆菌CNCM I-4319和鼠李糖乳杆菌CNCM I-4316公开于国际申请WO 2011/148220。
本发明的组合物可以是任何适于给药的形式，尤其是口服给药。这包括例如固体、半固体、液体和粉剂。通常优选液体组合物以易于给药，例如作为饮料。
本发明的组合物的实例是包括食品的营养组合物。组合物可以是例如乳制品，优选发酵乳制品。任选地，可以存在其它的乳酸菌菌株。在一个优选的实施方式中，存在嗜热链球菌和保加利亚乳杆菌菌株。发酵产品可以是液体形式或由干燥发酵液所获得的干燥粉末形式。优选地，发酵产品是新鲜产品。新鲜产品(其没有经历剧烈的热处理步骤)具有细菌菌株以活的形式存在的优点。发酵产品可以尤其是乳制品，更优选的是发酵乳和/或发酵乳清。例如，营养组合物是凝固的、搅拌的或可饮用形式的酸奶或发酵乳。发酵产品也可以是干酪或发酵植物，如凝固的、搅拌的或可饮用形式的发酵大豆、谷物和/或水果。本发明的营养组合物可以是婴儿食品、婴儿配方奶粉或后续婴儿配方奶粉。
本发明的组合物还可以是营养产品或药物产品、营养补充剂或医疗食品。
本发明的营养组合物还包括食品补充剂和功能食品。“食品补充剂”是指由通常在食品中使用的化合物所制造的产品，但所述化合物通常为与养料(aliment)无关的片剂、粉剂、胶囊剂、饮剂或任何的其它形式，并且对人的健康具有有益作用。“功能性食品”是也对人的健康具有有益作用的滋养品。特别地，食品补充剂和功能性食品可以对疾病(例如对慢性疾病)具有生理作用(防护或治疗)。
根据本发明的组合物可例如在每g干重中包括至少105个菌落形成单位(cfu)，优选至少106cfu的本发明的菌株(动物双歧杆菌动物亚种CNCM I-4602)。
在本发明的组合物中，细菌菌株尤其是动物双歧杆菌动物亚种CNCM I-4602可以以完整细菌(可以是活的或死的)的形式使用。或者，其可以以细菌裂解物的形式或以细菌部分的形式使用。可以选择适合于这一用途的细菌部分，例如，通过测试其缓解对本申请所述的共培养模型的VIP水平的作用的性质。优选地，细菌细胞以活的、有活性的细胞的形式存在。
当细菌是活细菌的形式时，组合物典型地可以在每g干重的组合物中包括105至1013cfu，优选至少106cfu，更优选至少107cfu，还更优选至少108cfu，和最优选至少109cfu。在液体组合物的情况下，这通常对应于104至1012cfu/ml，优选至少105cfu/ml，更优选至少106cfu/ml，还更优选至少107cfu/ml和最优选至少109cfu/ml。
本发明的菌株或组合物特别适用于预防和/或减轻胃肠不适或胃肠疾病。其可以施用于患有肠道不适或肠道疾病的受试者。因此，有利地用于预防或解决肠道不适或肠道疾病。此类不适或疾病包括例如与气体相关的不适或疾病、胃气胀、腹胀、腹痛、便秘，以及在一些严重的方面，肠易激综合征(IBS)和炎性肠疾病(IBD)。
根据一个具体的方面，菌株CNCM I-4602或根据本发明的组合物用于增加受试者中肠神经系统的血管活性肠肽(VIP)水平。更具体地，这种VIP水平的增加用于改善肠道运动性、改善肠道蠕动和/或降低肠渗透性，尤其是在患有选自如下疾病的受试者中：肠道运动性和/或渗透性疾病、肠易激综合征(IBS)如IBS-C、IBS-D和IBS-PI、炎性肠疾病(IBD)、便秘和肠道感染，或者是在选自老人、婴幼儿和肥胖者的受试者(其肠道功能总体上得到了改善)中。IBS(或痉挛性结肠)是特征为慢性腹痛、不适、鼓胀和在缺少任何可检测的器官原因的情况下改变排便习惯的功能性肠疾病。腹泻或便秘可能占主导地位，因此IBS分别被分为IBS-D或IBS-C，或可能两者交替。IBS可以开始于感染后(此时被称为IBS-PI(指感染后))，应激性生活事件后或没有任何其它医学指标的成熟开始后。
因此，本发明的组合物可用于治疗和/或预防选自肠道运动性疾病、肠道渗透性疾病、IBS(包括IBS-D、IBS-C和IBS-PI)、IBD、便秘和肠道感染的疾病，尤其是在老人或肥胖者或婴幼儿中。
具体实施方式
可以在下列非限制性实施例中找到本发明的详细说明或优点。
实施例1：在ENS原代培养物和T84细胞的共培养模型中乳酸菌对神经元VIP生产的作用
研究了与107种益生菌菌株相互作用后原代肠神经元对VIP生产的不同响应，其中益生菌菌株包括乳酸菌，尤其是双歧杆菌。
细菌菌株和生长条件
乳酸杆菌生长于Man、Rogosa和Sharpe(MRS)培养基(Biokar Diagnostics,Beauvais，法国)中，于37℃需氧条件下培养24小时。
双歧杆菌培养于确定的培养基中，此培养基由补充有葡萄糖(Sigma，法国)、酵母提取物(Becton Dickinson，美国)和氯化血红素(Calbiochem，法国)的胰蛋白胨(BectonDickinson，美国)组成，并于37℃在厌氧条件下生长24小时。动物双歧杆菌乳酸菌亚种培养于补充有半胱氨酸(Sigma，法国)的MRS培养基(Biokar Diagnostics)中，并于37℃在厌氧条件下生长24小时。
获得ENS原代培养物和T84细胞的共培养模型
共培养模型，其改编自Moriez等人(Biochem.Biophys.Res.Commun.,382(3):577-82,2009)开发的模型，其具有与肠上皮细胞T84细胞培养的肠神经元细胞，用于细菌的筛选。
如前所述(Chevalier等人,J.Physiol.,586(7):1963-75,2008)，获得大鼠ENS的原代培养物。
T84细胞系培养于补充有10％热灭活的FBS和50IU/ml青霉素和50μg/ml链霉素的DMEM-F12(1：1，GIBCO)中。以2×105个细胞/插入物的密度将细胞接种于12孔过滤器(Corning,NY，美国)并培养，以获得汇合。建立共培养前24小时，T84细胞的培养基被原代ENS培养基替代。
上皮细胞达到汇合后1天，将过滤器转移至底部接种有肠神经细胞的12孔板中。上皮细胞和神经元细胞共培养于上皮细胞的培养基中。
将细菌培养物在PBS中洗涤，并再悬浮于Dulbecco’s Modified Eagle Medium(DMEM)：Nutrient Mixture F-12(Ham’s)(1:1)培养基中，其包含1％的N-2补充剂(LifeTechnologies,Cergy-Pontoise，法国)。细菌的每种菌株至少一式三份进行测试以进行方差分析。以40个细菌/上皮细胞的MOI将菌株添加到过滤器隔室中。对照不加入细菌。共孵育8小时后，移除含有上皮细胞和细菌的过滤器隔室并将原代ENS培养物在恒温箱(95％空气，5％CO2)中于37℃保持22小时。在对照孔中，进行VIP测量时，用40mM KCl刺激神经元细胞。
VIP测量
然后，从12孔板中收集ENS细胞并用于制备蛋白提取物，以定量血管活性肠肽(VIP)。为了确定细胞内VIP，用含有蛋白酶抑制剂混合物(Roche Diagnostics,Meylan，法国)的RIPA裂解缓冲液(Millipore,Billerica,MA，美国)提取细胞内蛋白。用购买的酶免疫分析(EIA)试剂盒(Peninsula laboratories,Bachem,SA)定量VIP。
ENS模型的统计方法
根据下式，用阴性对照(T84)将所有的菌株VIP标记值归一化：(VIP菌株-VIPT84)/VIPT84。
根据其所估计的归一化值将菌株排序，其中所估计的归一化值来自具有作为固定影响的菌株的混合模型。模型给出了与每种菌株所估计的归一化值相关的P值。如果P值小于5％(<0.05)，则菌株作用是显著的。
结果
结果示于下述表1中。
表1
KCl，用作阳性对照，平均增加15.7％的VIP水平。
9个菌株能显著地增加VIP水平，从0.18％至62.5％。表1给出了其中7个所得到的结果。在9个菌株中，动物双歧杆菌动物亚种CNCM I-4602示出了最高水平的VIP增加。其与不存在任何菌株的水平相比，具有62.5％的增加。
在另一方面，观察到15个菌株显著地(P<0.05)降低了VIP水平。表1中示出了这15个菌株中的10个的结果。
所测试的其它菌株对VIP没有显著(P>0.05)的作用，其包括例如长双歧杆菌NCC2705(CNCM I-2618)、鼠李糖乳杆菌GG(ATCC 53103)、婴儿双歧杆菌(Bifidobacteriuminfantis)UCC 3564、长双歧杆菌Bb536、动物双歧杆菌乳酸菌亚种Bi-07(ATCC SD 5220)、约氏乳杆菌La1(CNCM I-1225)、植物乳杆菌299v(DSM 9843)和罗伊氏乳杆菌(Lactobacillus reuteri)SD 2112(ATCC 55730)。
Claims (18)
1.一种动物双歧杆菌动物亚种(Bifidobacterium animalis subspecies animalis)菌株，其于2012年3月6日保藏于CNCM(Collection Nationale de Cultures deMicroorganismes，法国国家微生物保藏中心)，保藏号为I-4602。
2.一种组合物，其包含权利要求1所述的菌株和至少一种其它的选自短双歧杆菌(Bifidobacterium breve)CNCM I-4321、短双歧杆菌CNCM I-2219、动物双歧杆菌乳酸菌亚种(Bifidobacterium animalis ssp.lactis)CNCM I-2494、植物乳杆菌(Lactobacillusplantarum)CNCM I-4318、两歧双歧杆菌(Bifidobacterium bifidum)CNCM I-4319和鼠李糖乳杆菌(Lactobacillus rhamnosus)CNCM I-4316的菌株。
3.如权利要求2所述的组合物，其是乳制品。
4.如权利要求2所述的组合物，其是发酵乳制品。
5.如权利要求2至4中任一项所述的组合物，其每g干重包括至少105cfu的动物双歧杆菌动物亚种CNCM I-4602。
6.如权利要求2至4中任一项所述的组合物，其每g干重包括至少106cfu的动物双歧杆菌动物亚种CNCM I-4602。
7.如权利要求1所述的菌株在制备用于预防和/或减轻胃肠不适或胃肠疾病的食品产品中的用途。
8.如权利要求1所述的菌株在制备用于增加受试者的肠神经系统的血管活性肠肽水平的食品产品中的用途。
9.如权利要求1所述的菌株在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的食品产品中的用途。
10.如权利要求7所述的用途，其中所述菌株被施与患有选自肠道运动性疾病、肠道渗透性疾病、便秘和肠道感染的疾病的受试者。
11.如权利要求7所述的用途，其中所述菌株被施与患有肠易激综合征的受试者。
12.如权利要求7所述的用途，其中所述菌株被施与患有炎性肠疾病的受试者。
13.如权利要求2至6中任一项所述的组合物在制备用于预防和/或减轻胃肠不适或胃肠疾病的食品产品中的用途。
14.如权利要求2至6中任一项所述的组合物在制备用于增加受试者的肠神经系统的血管活性肠肽水平的食品产品中的用途。
15.如权利要求2至6中任一项所述的组合物在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的食品产品中的用途。
16.如权利要求13所述的用途，其中所述组合物被施与患有选自肠道运动性疾病、肠道渗透性疾病、便秘和肠道感染的疾病的受试者。
17.如权利要求13所述的用途，其中所述组合物被施与患有肠易激综合征的受试者。
18.如权利要求13所述的用途，其中所述组合物被施与患有炎性肠疾病的受试者。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2012/057431 WO2014096901A1 (en) | 2012-12-18 | 2012-12-18 | Strain of bifidobacterium animalis ssp. animalis |
| IBPCT/IB2012/057431 | 2012-12-18 | ||
| PCT/IB2013/060774 WO2014097050A1 (en) | 2012-12-18 | 2013-12-10 | Strain of bifidobacterium animalis ssp. animalis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105025907A CN105025907A (zh) | 2015-11-04 |
| CN105025907B true CN105025907B (zh) | 2019-05-31 |
Family
ID=47633132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380065461.0A Active CN105025907B (zh) | 2012-12-18 | 2013-12-10 | 动物双歧杆菌动物亚种菌株 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10064902B2 (zh) |
| EP (1) | EP2934557B1 (zh) |
| JP (1) | JP6197045B2 (zh) |
| KR (1) | KR102146429B1 (zh) |
| CN (1) | CN105025907B (zh) |
| AR (1) | AR093916A1 (zh) |
| CA (1) | CA2893822C (zh) |
| EA (1) | EA030356B1 (zh) |
| ES (1) | ES2621264T3 (zh) |
| HU (1) | HUE032210T2 (zh) |
| MA (1) | MA38174A1 (zh) |
| MX (1) | MX358026B (zh) |
| PL (1) | PL2934557T3 (zh) |
| PT (1) | PT2934557T (zh) |
| TN (1) | TN2015000259A1 (zh) |
| WO (2) | WO2014096901A1 (zh) |
| ZA (1) | ZA201504217B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2725883C2 (ru) * | 2015-04-23 | 2020-07-07 | Компани Жервэ Данон | Композиция для сокращения выработки кишечного газа |
| WO2017021754A1 (en) * | 2015-07-31 | 2017-02-09 | Compagnie Gervais Danone | Methods for the preparation of fermented products comprising bifidobacteria |
| KR101910808B1 (ko) * | 2016-11-28 | 2018-10-24 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질 및 이의 항암 용도 |
| CN107574133A (zh) * | 2017-05-05 | 2018-01-12 | 南昌大学 | 动物双歧杆菌m2017064及其在缓解慢性肾脏疾病药物的应用 |
| KR101964883B1 (ko) | 2017-10-26 | 2019-04-02 | 서울대학교 산학협력단 | 한국 유아 분변 유래의 베타-갈락토시데이즈 활성이 우수한 신규 균주 비피도박테리움 애니멀리스 ldtm8101 |
| KR102238519B1 (ko) * | 2018-12-28 | 2021-04-13 | (주)메디톡스 | 외래 단백질을 발현하는 미생물, 및 그의 용도 |
| AU2019454505B2 (en) * | 2019-06-27 | 2023-07-20 | Ildong Pharmaceutical Co., Ltd. | Novel probiotic composition for regulation of intestinal immunity |
| CN111826299B (zh) * | 2020-01-22 | 2022-06-21 | 内蒙古蒙牛乳业（集团）股份有限公司 | 一种润肠通便的乳双歧杆菌及其应用与制剂 |
| KR20210129516A (ko) * | 2020-04-20 | 2021-10-28 | 주식회사 리비옴 | 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 |
| CN112159778B (zh) * | 2020-09-30 | 2021-12-03 | 江南大学 | 一株可缓解银屑病的动物双歧杆菌及其应用 |
| CN114717132B (zh) * | 2021-09-08 | 2023-07-07 | 青岛蔚蓝生物股份有限公司 | 一株具有预防和缓解便秘症状的乳双歧杆菌及其应用 |
| KR102495386B1 (ko) * | 2021-12-08 | 2023-02-06 | ㈜새롬바이오 | 유산균을 이용한 저글루텐 밀가루 발효조성물, 이를 포함하는 식품첨가제 및 이를 포함하는 식품, 및 그 제조 방법 |
| CN114350577B (zh) * | 2022-03-17 | 2022-05-27 | 微康益生菌(苏州)股份有限公司 | 一种改善便秘的动物双歧杆菌乳亚种BLa36及其培养方法与应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102123718A (zh) * | 2008-07-15 | 2011-07-13 | N.V.努特里奇亚 | 消化道运动性病症的治疗 |
| WO2011148219A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
| CN102711778A (zh) * | 2009-11-02 | 2012-10-03 | 热尔韦法国达能公司 | 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020044046A (ko) * | 2001-07-30 | 2002-06-14 | 비앤아이티(주) | 복합 생균제를 소재로 한 장기능 개선용 건강기능성식품 |
| EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| PL2403510T3 (pl) * | 2009-03-05 | 2020-06-29 | Probiotical S.P.A. | Szczepy bakteryjne o wysokiej aktywności przeciwzapalnej |
| AU2011209407B2 (en) * | 2010-01-28 | 2014-02-27 | Ab-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
| WO2011148220A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving transepithelial resistance |
-
2012
- 2012-12-18 WO PCT/IB2012/057431 patent/WO2014096901A1/en active Application Filing
-
2013
- 2013-12-10 EA EA201591057A patent/EA030356B1/ru not_active IP Right Cessation
- 2013-12-10 MX MX2015007814A patent/MX358026B/es active IP Right Grant
- 2013-12-10 PL PL13824023T patent/PL2934557T3/pl unknown
- 2013-12-10 HU HUE13824023A patent/HUE032210T2/hu unknown
- 2013-12-10 US US14/651,968 patent/US10064902B2/en active Active
- 2013-12-10 MA MA38174A patent/MA38174A1/fr unknown
- 2013-12-10 PT PT138240239T patent/PT2934557T/pt unknown
- 2013-12-10 CN CN201380065461.0A patent/CN105025907B/zh active Active
- 2013-12-10 JP JP2015547229A patent/JP6197045B2/ja active Active
- 2013-12-10 EP EP13824023.9A patent/EP2934557B1/en active Active
- 2013-12-10 CA CA2893822A patent/CA2893822C/en active Active
- 2013-12-10 WO PCT/IB2013/060774 patent/WO2014097050A1/en active Application Filing
- 2013-12-10 ES ES13824023.9T patent/ES2621264T3/es active Active
- 2013-12-10 KR KR1020157017301A patent/KR102146429B1/ko active IP Right Grant
- 2013-12-11 AR ARP130104626A patent/AR093916A1/es unknown
-
2015
- 2015-06-09 TN TNP2015000259A patent/TN2015000259A1/fr unknown
- 2015-06-11 ZA ZA2015/04217A patent/ZA201504217B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102123718A (zh) * | 2008-07-15 | 2011-07-13 | N.V.努特里奇亚 | 消化道运动性病症的治疗 |
| CN102711778A (zh) * | 2009-11-02 | 2012-10-03 | 热尔韦法国达能公司 | 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法 |
| WO2011148219A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
| WO2011148355A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
Non-Patent Citations (1)
| Title |
|---|
| 动物源双歧杆菌益生素的研究进展;李桂霞等;《中国畜牧兽医学会动物微生态学分会第三届第八次学术研讨会论文》;20061231;第101-104页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591057A1 (ru) | 2015-10-30 |
| CN105025907A (zh) | 2015-11-04 |
| WO2014097050A1 (en) | 2014-06-26 |
| KR20150095717A (ko) | 2015-08-21 |
| EA030356B1 (ru) | 2018-07-31 |
| PT2934557T (pt) | 2017-04-05 |
| CA2893822C (en) | 2021-09-21 |
| HUE032210T2 (hu) | 2017-09-28 |
| KR102146429B1 (ko) | 2020-08-20 |
| US20150320807A1 (en) | 2015-11-12 |
| TN2015000259A1 (en) | 2016-10-03 |
| EP2934557B1 (en) | 2017-01-04 |
| EP2934557A1 (en) | 2015-10-28 |
| WO2014096901A1 (en) | 2014-06-26 |
| CA2893822A1 (en) | 2014-06-26 |
| ES2621264T3 (es) | 2017-07-03 |
| JP2016502842A (ja) | 2016-02-01 |
| JP6197045B2 (ja) | 2017-09-13 |
| US10064902B2 (en) | 2018-09-04 |
| WO2014097050A9 (en) | 2014-11-06 |
| ZA201504217B (en) | 2017-08-30 |
| MX358026B (es) | 2018-08-02 |
| MX2015007814A (es) | 2015-08-20 |
| PL2934557T3 (pl) | 2017-08-31 |
| MA38174A1 (fr) | 2018-03-30 |
| AR093916A1 (es) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105025907B (zh) | 动物双歧杆菌动物亚种菌株 | |
| CN103209698B (zh) | 用于改善肠神经系统的益生菌菌株 | |
| JP4022779B2 (ja) | コレステロールを低下および同化する能力を有する酸および胆汁酸塩耐性のＬａｃｔｏｂａｃｉｌｌｕｓ分離株 | |
| CN102421889B (zh) | 来自完全以母乳喂养的婴儿粪便的具有益生活性的菌株的分离、鉴定和表征 | |
| CA2774073C (en) | Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance | |
| CN110892935A (zh) | 一株用于治疗便秘和腹泻的乳双歧杆菌及其应用 | |
| WO2008114503A1 (en) | Composition for improving intestinal microflora | |
| TW201834673A (zh) | 包含猴頭菇的益生菌組合物 | |
| WO2005095656A1 (en) | Lactic acid bacteria strains exhibiting probiotic properties and compositions comprising the same | |
| CN109715784A (zh) | 细菌 | |
| EP1424075A2 (en) | Acid and bile-resistant lactobacillus isolates having the ability to lower and addimilate cholesterol | |
| JP5980785B2 (ja) | 新規ビフィズス菌及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |